Introduction
Pemitinib 13.5 mg is identified as a product containing pemigatinib, an oral targeted anticancer medicine that inhibits FGFR1, FGFR2 and FGFR3.
The appropriate dosage of pemigatinib depends on the condition being treated, the patient’s medical circumstances and the applicable prescribing information.
Pemigatinib has different treatment schedules for its recognized indications. For this reason, patients must understand that the dosage used for FGFR2-altered cholangiocarcinoma is not the same as the schedule used for FGFR1-rearranged myeloid/lymphoid neoplasms.
The information below describes the U.S. reference-product prescribing schedules for educational purposes. It is not an individualized prescription for Pemitinib.
Recommended Dosage for FGFR2-Altered Cholangiocarcinoma
Under U.S. prescribing information for the reference product, the recommended pemigatinib dosage for eligible adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma containing an FGFR2 fusion or qualifying rearrangement is:
13.5 mg orally once daily for 14 consecutive days, followed by seven days without treatment.
One complete treatment cycle lasts 21 days.
21-day treatment cycle
Days 1–14
Treatment days
13.5 mg daily
Take the prescribed dose once daily for 14 consecutive days.
Days 15–21
Rest period
7 days off
Do not take pemigatinib during the scheduled seven-day break.
After the seven-day break, the next cycle begins according to the treatment plan prescribed by the oncology specialist.
The treating specialist determines how long treatment should continue based on disease status, treatment response, tolerability and adverse reactions.
Recommended Dosage for FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
Under U.S. prescribing information, the recommended pemigatinib dosage for eligible adults with relapsed or refractory myeloid/lymphoid neoplasms containing an FGFR1 rearrangement is:
13.5 mg orally once daily on a continuous schedule.
Unlike the cholangiocarcinoma schedule, this regimen does not include a routine seven-day break after every 14 days.
Patients must follow the treatment schedule prescribed for their specific diagnosis.
How to Take Pemitinib
Pemigatinib is an oral medicine.
General administration instructions for the reference product include:
- Take the prescribed tablet by mouth once daily.
- Swallow the tablet whole with water.
- Do not crush, chew, split or dissolve the tablet.
- It may be taken with or without food.
- Try to take the medicine at approximately the same time each day.
- Follow the prescribed treatment calendar.
- Do not change the dose without medical advice.
The medicine should be handled according to the instructions provided with the actual product.
Should Pemigatinib Be Taken Before or After Food?
Pemigatinib may be taken with or without food under the reference-product administration instructions.
Patients do not generally need to coordinate their dose with a particular meal.
However, maintaining a consistent daily routine may help patients remember their prescribed treatment.
If nausea, appetite changes or other digestive symptoms occur, patients should discuss appropriate management with their healthcare professional.
What to Do If You Miss a Dose
If a patient misses a dose, the U.S. reference-product instructions specify that the missed dose may be taken if the next dose is at least four hours away.
If the next scheduled dose is less than four hours away, the missed dose should be skipped.
The patient should then take the next dose at its usual scheduled time.
An extra dose should not be taken to compensate for a missed dose.
What to Do If You Vomit After Taking Pemigatinib
If vomiting occurs after taking pemigatinib, another dose should not be taken to replace the dose that may have been vomited.
The patient should take the next scheduled dose at the usual time.
Taking an additional tablet may result in an unintended increase in medication exposure.
Dose Adjustments
Dose adjustments may be necessary if a patient experiences significant adverse reactions or has certain medical conditions.
The prescribing information provides dose-reduction instructions for specific situations.
For the reference product, dose levels used in dose modification include:
| Dose level | Daily dose |
|---|---|
| Starting dose | 13.5 mg |
| First reduction | 9 mg |
| Second reduction | 4.5 mg |
The appropriate dose reduction depends on the indication, the adverse reaction and the patient’s clinical condition.
Patients should not independently reduce, increase or interrupt their dose.
Dosage in Kidney or Liver Impairment
Kidney and liver function may influence how pemigatinib should be administered.
Under U.S. reference-product prescribing information, patients with severe renal impairment or severe hepatic impairment may require a reduced starting dose.
The labeled reduced starting dose for these circumstances is 9 mg once daily, using the appropriate treatment schedule for the indication.
The assessment of kidney and liver impairment must be made by a healthcare professional using appropriate clinical information.
Patients should not use a reduced dose simply because they have a general history of kidney or liver disease.
Monitoring During Treatment
Regular monitoring is important throughout pemigatinib treatment.
Blood phosphate monitoring: Pemigatinib can increase phosphate levels. Blood tests help identify hyperphosphatemia and guide appropriate management.
Eye examinations: Ocular toxicity, including retinal pigment epithelial detachment, is an important safety concern. Baseline and follow-up eye examinations are recommended under reference-product prescribing information.
Kidney and liver assessment: Organ function may affect treatment decisions and dose adjustments.
Skin and nail monitoring: Nail disorders, dry skin and other skin reactions may develop during therapy.
General treatment assessment: Healthcare professionals may evaluate fatigue, diarrhea, nausea, appetite changes, mouth inflammation and other adverse reactions.
Important Drug Interaction Precautions
Pemigatinib is affected by certain drug-metabolizing enzymes, particularly CYP3A.
Strong or moderate CYP3A inducers may reduce pemigatinib exposure, while strong or moderate CYP3A inhibitors may increase exposure.
These interactions can affect treatment effectiveness or safety.
Patients should tell their healthcare professionals about all medicines, vitamins, supplements and herbal products they use.
Grapefruit and grapefruit juice should also be discussed with the treating healthcare professional because they may affect drug metabolism.
What If Side Effects Occur?
Patients should report persistent, severe or unusual symptoms during treatment.
Dose interruption, reduction or discontinuation may be necessary depending on the type and severity of the adverse reaction.
Visual changes require prompt medical evaluation.
Patients should not attempt to manage serious adverse reactions by changing their treatment schedule independently.
Important Reminder
The dosage information on this page is based on U.S. reference-product prescribing information for pemigatinib. It does not independently verify the formulation, regulatory approval or dosing instructions of every Pemitinib-branded product.
Always follow the prescribing instructions supplied with the actual medicine and the directions of the treating specialist.